Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs

Journal of Pharmacy and Pharmacology

Volumn 54, Issue 7, 2002, Pages 921-927

  Furuya, A ^a   Nozawa, M ^a   Gotoh, J ^a   Jingu, S ^a   Akimoto, M ^a   Higuchi, S ^a   Suwa, T ^a   Ogata, H ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[4 [[5 (2 CARBOXYETHYL)CARBAMOYL] 3,4 DIMETHYL 2(3H) THIAZOLIDENE]CARBAMOYL]BEZIMIDOYL]AMINO]BUTYRIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; TS 943; UNCLASSIFIED DRUG; AMIDINE; FIBRINOGEN RECEPTOR; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; BOLUS INJECTION; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; FIBRINOLYSIS; HUMAN VERSUS ANIMAL COMPARISON; IC 50; MALE; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PLASMA; STATISTICAL MODEL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; DRUG ANTAGONISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION;

AMIDINES; ANIMAL; DOGS; HUMAN; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THIAZOLES; ANIMALS; HUMANS;

EID: 0035990538     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/002235702760089036     Document Type: Article

References (13)

1. Pharmacodynamics and pharmacokinetics of MK-383, selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men
2. Aggregation of blood platelets by adenosine diphosphate and its reversal
3. Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration
4. Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: A population approach
5. Population pharmacokinetics and pharmacodynamics of TS-943 for selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist in normal healthy subjects
6. Pharmacodynamics and pharmacokinetics of DMP728, a platelet GPIIb/IIIa antagonist, in healthy subjects
7. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist
8. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
9. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Inhibition of thrombosis by a selective fibrinogen receptor antagonist without effect on bleeding time
10. The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods
11. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)